IL295186A - Paste comprising magnetic alkoxysilane-coated metal containing nanoparticles - Google Patents

Paste comprising magnetic alkoxysilane-coated metal containing nanoparticles

Info

Publication number
IL295186A
IL295186A IL295186A IL29518622A IL295186A IL 295186 A IL295186 A IL 295186A IL 295186 A IL295186 A IL 295186A IL 29518622 A IL29518622 A IL 29518622A IL 295186 A IL295186 A IL 295186A
Authority
IL
Israel
Prior art keywords
paste
iron
still
alkoxysilane
magnetic
Prior art date
Application number
IL295186A
Other languages
Hebrew (he)
Inventor
GERBES Stefan
Jordan Andreas
Original Assignee
Magforce Ag
GERBES Stefan
Jordan Andreas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Magforce Ag, GERBES Stefan, Jordan Andreas filed Critical Magforce Ag
Publication of IL295186A publication Critical patent/IL295186A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Soft Magnetic Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Conductive Materials (AREA)
  • Powder Metallurgy (AREA)

Description

Paste comprising magnetic alkoxysilane-coated metal containing nanoparticles Magnetofluids comprising magnetic alkoxysilane-coated nanoparticles are known in the art. For example, aqueous suspensions comprising magnetic alkoxysilane-coated metal containing nanoparticles, methods of producing them and their use in the treatment of proliferative diseases have been described in WO 2013/020701.
Magnetofluids comprising magnetic alkoxysilane-coated nanoparticles are injected into tumors for treating the tumors by hyperthermia upon applying an alternating magnetic field. Therein, the nanoparticles agglomerate and form a depot, a kind of implant. Since more than one depot can be generated by this process, the entirety of all depots in their shape, position and distribution determines the temperature distribution that is achieved when the particles are subsequently activated in the tumor by an alternating magnetic field. Optimally, the tumor is covered exactly by the therapeutically necessary minimum temperature and the areas of high temperature in which the tissue is directly killed lie exclusively within the tumor.
When injected into tumor, it may take some time before the magnetofluid solidifies due to the agglomeration of the magnetic alkoxysilane-coated nanoparticles. This process takes place in a nanoparticle depot from the outside to the inside, whereby the solid surface can tear, so that nanoparticles can flow off through cracks following internal surfaces, gaps or other weak points in the tissue into other areas outside the target area. Thus, the desired particle distribution in the tumor tissue cannot be achieved and, consequently, the desired therapeutic temperatures cannot be reached in the tumor tissue or healthy tissue may be damaged. This is a problem especially with small tumors.
Accordingly, there is a need to provide alternative magnetic particle compositions which avoid the flowing off of magnetic nanoparticles into areas outside the target area after injection into a target site.
The present invention relates to a magnetic particle composition which overcomes the disadvantage of deferred solidification after injection into the target site and the further DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] 2 disadvantage of spreading and scattering of the nanoparticles or agglomerates of nanoparticles into neighboring tissue.
The inventors of the present invention have surprisingly found that a particular pasty composition, i.e. a composition in the form of a paste, can be provided by thermal treatment when taking an aqueous suspension comprising magnetic alkoxysilane-coated metal containing nanoparticles as a starting material. A pasty composition or paste is characterized by the presence of yield stress and by shear thinning behavior; allowing the paste on the one hand to be drawn up into e.g. a syringe, e.g. via a needle, or into a cannula. Upon injection into a tumor, but on the other hand to remain at the site of injection, as it is injected into the tumor as a composition which, after injection, immediately adopts a non-movable state, as compared to a fully liquid suspension which did not undergo any thermal treatment. This immobilization prevents the flowing off of nanoparticles and agglomerates into non-target area.
The present invention provides a paste comprising agglomerates of magnetic alkoxysilane-coated metal containing nanoparticles which can be injected in the daily routine precisely into tissue and remains at the injection site, without spreading or substantially spreading to surrounding tissue. This allows a more accurate hyperthermia treatment particularly of small tumors and of tumorous tissue in the vicinity of channels, where the suspension of magnetic nanoparticles would otherwise leave the treatment area. Furthermore, the present invention provides a manufacturing process for such paste.
In the following, the present invention is disclosed in detail. The features of the present invention are described in individual paragraphs. This, however, does not mean that a feature described in a paragraph stands isolated from a feature or features described in other paragraphs. Rather, a feature described in a paragraph can be combined with a feature or features described in other paragraphs.
In a first aspect, the present invention provides a paste comprising agglomerates of magnetic alkoxysilane-coated metal containing nanoparticles obtainable by a method, wherein the method comprises the step of thermally treating an aqueous suspension comprising agglomerates of magnetic alkoxysilane-coated metal containing nanoparticles.
In a preferred embodiment of the invention, the paste is characterized by plastic behavior.
DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] 3 In a further preferred embodiment of the invention, the paste is characterized by the presence of yield stress. The yield stress is preferably between 0.03 and 80 Pa, more preferably between 0.06 and 70 Pa, still more preferably between 0.1 and 40 Pa and most preferably between 1 and 35 Pa.
In an equally preferred embodiment, the paste has a shear thinning behavior.
In a preferred embodiment of the invention, the paste is characterized by a viscosity, wherein the viscosity of the paste is between 0.03 and 7 Pa s, more preferably between 0.03 and 5 Pa s, still more preferably between 0.08 and 3.5 Pa s, still more preferably between 0.1 and 3.5 Pa s, still more preferably between 0.1 and 3.0 Pa s, still more preferably between 0.5 and 3.0 Pa s, still more preferably between 0.7 and 3.0 Pa s, still more preferably between 1 and 3.0 Pa, measured at a shear rate of 50/s.
In a preferred embodiment of the invention, the step of thermally treating is carried out at a temperature between 25 and 130ºC, preferably between 30 and 120ºC, more preferably between 40 and 100ºC, still more preferably between 40 and 80ºC, still more preferably between 40 and 60 ºC.
In a preferred embodiment of the invention, the step of thermally treating is carried out for a time period of between 0.1 to 96 hours (hrs), preferably for a time period of between 0.5 to 72 hours (hrs), more preferably for a time period of between 1 to 48 hours (hrs).
In an another preferred embodiment of the invention, the aqueous suspension comprises a concentration of at least about 2 M, preferably of at least about 3 M, more preferably of at least about 4 M, even more preferably of at least about 5 M, and especially of at least about 6 M, to about 8, 9 or 10 M, as determined by its metal content.
In yet another preferred embodiment of the invention, the method further comprises the step of incubating the aqueous suspension of magnetic metal containing nanoparticles with an alkoxysilane before thermally treating the aqueous suspension.
In an embodiment of the invention, the step of incubating is carried out in the absence of an added organic solvent.
In an embodiment of the invention, the alkoxysilane is a trialkoxysilane, preferably selected from the group consisting of 3-(2-aminoethylamino)-propyl-trimethoxysilane, 3- DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] 4 aminopropyltriethoxysilane, trimethoxysilylpropyl-diethylenetriamine and N-(6- aminohexyl)-3-aminopropyltrimethoxysilane, especially 3-(2-aminoethylamino)-propyl- -3 -3 trimethoxysilane, and/or 0.3 to 0.6 x 10 mol, preferably 0.4 to 0.5 x 10 mol, more -3 preferably 0.43 to 0.45 x 10 mol, alkoxysilane per 0.9 mol metal is added in the incubating step.
In an embodiment of the invention, the magnetic metal containing nanoparticles comprise iron, iron complex compounds, iron carbonyl compounds or iron salts, preferably iron salts, more preferably wherein the iron salt is an iron oxide, preferably magnetite and/or maghemite.
In an embodiment of the invention, the iron oxide nanoparticles are provided (a) by precipitating a solution containing a mixture of iron(III) chloride and iron(II) chloride with sodium hydroxide, or (b) by thermal decomposition of an iron salt or an iron complex compound.
In an embodiment of the invention, the method further comprises the step of ultrasound treatment of the aqueous suspension of magnetic metal containing nanoparticles before thermally treating the aqueous suspension.
In an embodiment of the invention, the specific absorption rate (SAR) of the nanoparticles is larger or equal than 2 W/g Me, preferably larger or equal than 3 W/g Me, more preferably 4 to 12 W/g Me, as determined at a magnetic field strength of 3.5 kA/m and a frequency of 100 kHz.
In a further aspect, the present invention relates to a medical device comprising the paste of the present invention.
In another aspect, the invention relates to a pharmaceutical composition comprising the paste of the present invention.
In yet another aspect, the paste of the invention is for use in a method for treating or preventing proliferative disease, cancer, tumor, rheumatism, arthritis, arthrosis or bacterial infection in a patient.
DynamicPDF for .NET v8.0.0.40 (Build 29393)Evaluating unlicensed DynamicPDF feature. Click here for details. [4:0:v8.0] In a further aspect, the pharmaceutical composition comprising the paste of the invention is for use in a method for treating or preventing proliferative disease, cancer, tumor, rheumatism, arthritis, arthrosis or bacterial infection in a patient.
Equally, the present invention relates to a method of preventing or treating a proliferative disease, cancer, tumor, rheumatism, arthritis, arthrosis or bacterial infection in a subject in need thereof, comprising administering the paste or the pharmaceutical composition of the invention to the subject in need thereof.
In yet another aspect, the present invention provides a method for producing the paste of the invention, wherein the method comprising any of the steps as detailed above.
In particular, the method comprises the step of thermally treating an aqueous suspension comprising agglomerates of magnetic alkoxysilane-coated metal containing nanoparticles.
This thermal treating step may be carried out at a temperature between 25 and 130ºC, preferably between 30 and 120ºC, more preferably between 40 and 100ºC, still more preferably between 40 and 80ºC, still more preferably between 40 and 60ºC, and/or for a duration of time of between 0.1 to 96 h, preferably 0.5 to 72 h, more preferably 1 to 48 h.
Preferably, the aqueous suspension comprises a concentration of at least about 2 M, preferably of at least about 3 M, more preferably of at least about 4 M, even more preferably of at least about 5 M, and especially of at least about 6 M, to about 8, 9 or 10 M, as determined by its metal content. The method may further comprise the step of incubating the aqueous suspension comprising magnetic metal containing nanoparticles with an alkoxysilane before the step of thermally treating the aqueous suspension. The incubating step may be carried out in the absence of an added organic solvent. The alkoxysilane may be a trialkoxysilane, preferably selected from the group consisting of 3- (2-aminoethylamino)-propyl-trimethoxysilane, 3-aminopropyltriethoxysilane, trimethoxysilylpropyl-diethylenetriamine and N-(6-aminohexyl)-3- aminopropyltrimethoxysilane, especially 3-(2-aminoethylamino)-propyl-trimethoxysilane. -3 -3 -3 0.3 to 0.6 x 10 mol, preferably 0.4 to 0.5 x 10 mol, more preferably 0.43 to 0.45 x 10 mol, alkoxysilane per 0.9 mol metal may be added in the incubating step. The magnetic metal containing nanoparticles may comprise iron, iron complex compounds, iron carbonyl compounds or iron salts, preferably iron salts, more preferably wherein the iron salt is an iron oxide, preferably magnetite and/or maghemite, whereby the iron oxide nanoparticles may be provided by precipitating a solution containing a mixture of iron(III) chloride and iron(II) chloride with sodium hydroxide, or by thermal decomposition of an iron salt or an iron complex compound.

Claims (14)

  1. Claims 1. A paste comprising agglomerates of magnetic alkoxysilane-coated metal containing nanoparticles obtainable by a method, wherein the method comprises the step of thermally treating an aqueous suspension comprising agglomerates of magnetic alkoxysilane-coated metal containing nanoparticles.
  2. 2. The paste of claim 1, wherein the paste is characterized by plastic behavior.
  3. 3. The paste of claim 1 or 2, wherein the paste is characterized by the presence of yield stress, wherein the yield stress is preferably between 0.03 and 80 Pa, more preferably between 0.06 and 70 Pa, still more preferably between 0.1 and 40 Pa and most preferably between 1 and 35 Pa.
  4. 4. The paste of any one of claims 1 to 3, wherein the paste has a shear thinning behavior. 5. The paste of any one of claims 1 to 4, wherein the past is characterized by a viscosity of between 0.03 and 7 Pa s, more preferably of between 0.03 and 5 Pa s, still more preferably of between 0.08 and 3.5 Pa s, still more preferably of between 0.1 and 3.
  5. 5 Pa s, still more preferably of between 0.1 and 3.0 Pa s, still more preferably of between 0.5 and 3.0 Pa s, still more preferably of between 0.7 and 3.0 Pa s, still more preferably of between 1 and 3.0 Pa, measured at a shear rate of 50/s.
  6. 6. The paste of any one of claims 1 to 5, wherein the step of thermally treating is carried out at a temperature of between 25 and 130ºC, preferably of between 30 and 120ºC, more preferably of between 40 and 100ºC, still more preferably of between 40 and 80ºC, still more preferably of between 40 and 60 ºC.
  7. 7. The paste of any one of claims 1 to 6, wherein the step of thermally treating is carried out for a time period of between 0.1 to 96 hours, preferably for a time period of 0.5 to 72 hours, more preferably for a time period of 1 to 48 hours. 36
  8. 8. The paste of any one of claims 1 to 7, wherein the aqueous suspension comprises a concentration of at least about 2 M, preferably of at least about 3 M, more preferably of at least about 4 M, even more preferably of at least about 5 M, and especially of at least about 6 M, to about 8, 9 or 10 M, as determined by its metal content.
  9. 9. The paste of any one of claims 1 to 8, wherein the method further comprises the step of incubating the aqueous suspension of magnetic metal containing nanoparticles with alkoxysilane before thermally treating the aqueous suspension.
  10. 10. The paste of any one of claims 1 to 9, wherein the step of incubating is carried out in the absence of an added organic solvent.
  11. 11. The paste of any one of claims 1 to 10, wherein the alkoxysilane is a trialkoxysilane, preferably selected from the group consisting of 3-(2-aminoethylamino)-propyl- trimethoxysilane, 3-aminopropyltriethoxysilane, trimethoxysilylpropyl- diethylenetriamine and N-(6-aminohexyl)-3-aminopropyltrimethoxysilane, especially 3-(2-aminoethylamino)-propyl-trimethoxysilane, and/or -3 -3 0.3 to 0.6 x 10 mol, preferably 0.4 to 0.5 x 10 mol, more preferably 0.43 to 0.45 x -3 10 mol, alkoxysilane per 0.9 mol metal is added in the incubating step.
  12. 12. The paste of any one of claims 1 to 11, wherein the magnetic metal containing nanoparticles comprise iron, iron complex compounds, iron carbonyl compounds or iron salts, preferably iron salts, more preferably wherein the iron salt is an iron oxide, preferably magnetite and/or maghemite.
  13. 13. The paste of any one of claims 1 to 12, wherein the iron oxide nanoparticles are provided (a) by precipitating a solution containing a mixture of iron(III) chloride and iron(II) chloride with sodium hydroxide, or (b) by thermal decomposition of an iron salt or an iron complex compound.
  14. 14. The paste of any one of claims 1 to 13, wherein the method further comprises the step of ultrasound treatment of the aqueous suspension of magnetic metal containing nanoparticles before thermally treating the aqueous suspension. 37 15. The paste of any one of claims 1 to 14, wherein the specific absorption rate (SAR) of the nanoparticles is larger or equal than 2 W/g Me, preferably larger or equal than 3 W/g Me, more preferably 4 to 12 W/g Me, as determined at a magnetic field strength of 3.5 kA/m and a frequency of 100 kHz. 16. A medical device comprising the paste of any one of claims 1 to 15. 17. A pharmaceutical composition comprising the paste of any one of claims 1 to 15. 18. The paste of any one of claims 1 to 15 or the pharmaceutical composition of claim 17 for use in a method for preventing or treating a proliferative disease, cancer, tumor, rheumatism, arthritis, arthrosis or a bacterial infection in a subject in need thereof. 19. A method for producing the paste of any one of claims 1 to 15, wherein the method comprises the step of thermally treating an aqueous suspension comprising agglomerates of magnetic alkoxysilane-coated metal containing nanoparticles. 20. The method of claim 19, wherein the method is further characterized by any of the steps as defined in any one of claims 6 to 14. Dr. Revital Green Patent Attorney G.E. Ehrlich (1995) Ltd. 35 HaMasger Street Sky Tower, 13th Floor Tel Aviv 6721407
IL295186A 2020-01-31 2021-01-29 Paste comprising magnetic alkoxysilane-coated metal containing nanoparticles IL295186A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20154864 2020-01-31
PCT/EP2021/052178 WO2021152136A1 (en) 2020-01-31 2021-01-29 Paste comprising magnetic alkoxysilane-coated metal containing nanoparticles

Publications (1)

Publication Number Publication Date
IL295186A true IL295186A (en) 2022-09-01

Family

ID=69423158

Family Applications (1)

Application Number Title Priority Date Filing Date
IL295186A IL295186A (en) 2020-01-31 2021-01-29 Paste comprising magnetic alkoxysilane-coated metal containing nanoparticles

Country Status (4)

Country Link
EP (1) EP4096624A1 (en)
KR (1) KR20220133893A (en)
IL (1) IL295186A (en)
WO (1) WO2021152136A1 (en)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19614136A1 (en) 1996-04-10 1997-10-16 Inst Neue Mat Gemein Gmbh Process for the production of agglomerate-free nanoscale iron oxide particles with a hydrolysis-resistant coating
JP2001525833A (en) * 1997-05-23 2001-12-11 バイエル・アクチエンゲゼルシヤフト Organosilane-oligomer
US20050090732A1 (en) 2003-10-28 2005-04-28 Triton Biosystems, Inc. Therapy via targeted delivery of nanoscale particles
DE102005016873A1 (en) 2005-04-12 2006-10-19 Magforce Nanotechnologies Ag New nano-particle useful for production of composition to treatment and/or prophylaxis of proliferative illnesses, cancer and bacterial infections, where nano-particle is bonded therapeutic substance
DE102008003615A1 (en) 2008-01-09 2009-07-16 Magforce Nanotechnologies Ag Magnetic transducers
DE102008008522A1 (en) 2008-02-11 2009-08-13 Magforce Nanotechnologies Ag Implantable nanoparticle-containing products
DE102009058769A1 (en) 2009-12-16 2011-06-22 MagForce Nanotechnologies AG, 10589 Temperature-dependent activation of catalytic nucleic acids for controlled drug release
MX377929B (en) 2011-08-10 2025-03-10 Magforce Ag AGGLOMERATION OF NANOPARTICLES COATED WITH MAGNETIC ALKOXYSILANE.

Also Published As

Publication number Publication date
KR20220133893A (en) 2022-10-05
EP4096624A1 (en) 2022-12-07
WO2021152136A1 (en) 2021-08-05

Similar Documents

Publication Publication Date Title
US9162079B2 (en) Activatable particles, preparations and uses
Ciofani et al. A bi-modal approach against cancer: magnetic alginate nanoparticles for combined chemotherapy and hyperthermia
EP3058949B1 (en) Sensitizing composition using electromagnetic waves for thermal therapy of cancers, and cancer therapy using same
Liu et al. Polydopamine nanoparticles for deep brain ablation via near-infrared irradiation
US12397167B2 (en) Compositions and methods of altering the electric impedance to an alternating electric field
US9138476B2 (en) Nanoparticle-assisted ultrasound for cancer therapy
JP2008260705A (en) Injectable composition
CN104688773A (en) Cell killer
KR101513841B1 (en) Agglomerating magnetic alkoxysilane-coated nanoparticles
IL295186A (en) Paste comprising magnetic alkoxysilane-coated metal containing nanoparticles
CN108525128B (en) Application of liquid metal as tumor magnetic thermal therapy medium
RU2611715C1 (en) Method of increasing essential elements in body of broiler chickens in single muscular injection of highly dispersed nanoparticles of copper
Ikeda et al. Preparation of biopex-supported gold nanoparticles as potential fiducial markers for image-guided radiation therapy
EP1940295A2 (en) Resonant nanostructures and methods of use
CN118202817A (en) Piezoelectric shear-thinning material compositions and methods of use
TW202131955A (en) Methods of enhancing the accuracy or sensitivity of ultrasound imaging in diagnosing tumors
US20240050727A1 (en) Devices for forming in situ microneedles and methods thereof
CN103755643A (en) Rosuvastatin calcium I crystal form
CN102703510A (en) Carbon-coated magnetic nanoparticle gene transfection kit and purposes thereof
Yan et al. Chemical tools and materials for biological/medicinal applications
ITO et al. Complete regression of hereditary melanoma in a mouse model by repeated hyperthermia using magnetite cationic liposomes
CN121371210A (en) Magneto-electric nano carrier and preparation method and application thereof
CN121287951A (en) A method for clearing and detoxifying HPV infection inflammation
Tawfeeq Genotoxicity of silver nanoparticles synthesized by laser ablation method in vivo
HK40122383A (en) Compositions and methods of altering the electric impedance to an alternating electric field